Patrick John Finn, President and Chief Operating Officer of Twist Bioscience Corp (NASDAQ:TWST), filed a Form 4 on August 20, 2026, disclosing the exercise of stock options and sale of common stock on August 18, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Finn exercised stock options covering 23,355 shares of common stock at an exercise price of $67.85 per share on August 18, 2026.
  • Total shares sold: Finn disposed of 78,355 shares of common stock across seven separate sale transactions on August 18, 2026.
  • Sale price range: The weighted average sale prices across transactions ranged from $115.899 to $122.581 per share, with individual share prices spanning $115.35 to $122.815.
  • Remaining ownership: Following all reported transactions, Finn directly beneficially owned 214,678 shares of common stock.
  • 10b5-1 plan: All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Finn on May 18, 2026.
  • Option expiration: The exercised stock option carried an expiration date of August 31, 2030, and was 100% exercisable as of December 19, 2022, according to the filing.

Finn's Option Exercise and Multi-Tranche Share Sales at Twist Bioscience

According to the Form 4 filed with the SEC, Finn first acquired 23,355 shares through the exercise of a stock option at $67.85 per share (transaction code M), bringing his directly held position to 293,033 shares before subsequent sales. The exercised option had a conversion price of $67.85 and an expiration date of August 31, 2030. The filing notes the option "was 100% exercisable on December 19, 2022."

Finn then disposed of shares across seven sale transactions (transaction code S) on the same date. The tranches were: 33,354 shares at a weighted average of $115.899; 10,420 shares at $116.8202; 8,868 shares at $117.697; 4,500 shares at $119.04; 12,917 shares at $119.858; 6,296 shares at $121.007; and 2,000 shares at $122.581. Each price reported is a weighted average, and the filing states that full information on shares sold at each specific price is available upon request to the SEC, the issuer, or a security holder.

The filing confirms all transactions were made pursuant to a Rule 10b5-1 trading plan that Finn previously adopted on May 18, 2026. The Form 4 was signed by Kendra Fox as Attorney-in-Fact for Patrick John Finn and filed on August 20, 2026. After all reported activity, Finn's direct beneficial ownership of Twist Bioscience common stock stood at 214,678 shares.

What Was Disclosed

The filing disclosed a stock option exercise of 23,355 shares and the subsequent sale of 78,355 shares of Twist Bioscience common stock by President and COO Patrick John Finn on August 18, 2026, all under a pre-established Rule 10b5-1 trading plan adopted May 18, 2026.